Top Markets
Coin of the day
Graphite Bio, Inc. Graphite Bio, Inc.

Graphite Bio, Inc.

GRPH
Classement en actions #12750
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Prix de l'action
$22.26
Dernière synchronisation: 2024-03-22
Capitalisation boursière
$553.40M
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Graphite Bio, Inc. (GRPH)

Catégorie

Ratio P/S pour Graphite Bio, Inc. (GRPH)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Graphite Bio, Inc., le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Graphite Bio, Inc. de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH